Introduction
PRES is a serious neurological disorder of (sub) acute onset
characterized by abnormalities in cerebral white matter. Clinical
symptoms may include headaches, visual disturbances, disorders of
consciousness, seizures, or focal neurological deficits [1]. PRES
develops frequently in the context of cytotoxic medication, (pre)
eclampsia, sepsis, renal disease, or autoimmune disorders [1].
Among drugs, PRES may complicate calcineurin inhibitors such as
cyclosporine A (CSA). Organ-transplanted patients and those with
nephrotic syndrome on this drug have reportedly experienced this
complication [2, 3, and 4].
This article reports a unique and challenging case of a 16-year-old boy
admitted to our department with steroid-resistant nephrotic syndrome
(NS) and COVID-19 in February 2022. SARS-CoV-2 infection misled the
diagnosis of CSA-induced PRES.